Science Explorer Back to mapMap
Discussion
Topic · Oncology

Inflammatory Biomarkers in Disease Prognosis

Inflammatory Biomarkers in Disease Prognosis is a research topic within Oncology. Science Explorer counts 27k research works in it since 1951. 10.0% of them reached the world's top 10% most cited for their field and year.

This cluster of papers explores the intricate relationship between inflammation and cancer, focusing on the role of immunity, systemic inflammatory response, platelets, and various prognostic markers in cancer development, progression, and treatment effectiveness. It delves into the mechanisms of inflammation-induced cancer, the impact of platelets on metastasis, and the potential of inflammatory pathways as therapeutic targets.

  • Inflammation
  • Cancer
  • Immunity
  • Neutrophil-to-Lymphocyte Ratio
  • Platelets
  • Tumor Microenvironment
  • Systemic Inflammatory Response
  • Metastasis
  • Thrombosis
  • Prognostic Markers
Research works
27k
fractional, since 1951
In the world top 10%
2.7k
per year above
Top-10% rate
10.0%
share of its works in the world top 10%
Growth, 2018-21 → 2022-25
+44%
the tick is no change
Largest producer
China
52% of the 10 largest, 2022-now
Inflammatory Biomarkers in Disease Prognosis

This ranks research output and citation impact. It says nothing about the quality of diagnosis, treatment or care.

Which countries lead Inflammatory Biomarkers in Disease Prognosis research?

By volume, China and Türkiye publish the most (4.4k and 982 works in 2022-now).

By volume, 2022-now

  1. 1 China 4.4k works
  2. 2 Türkiye 982 works
  3. 3 United States 918 works
  4. 4 Japan 602 works
  5. 5 India 420 works
  6. 6 Indonesia 341 works
  7. 7 Italy 253 works
  8. 8 South Korea 233 works
  9. 9 United Kingdom 196 works
  10. 10 Germany 175 works

How concentrated that is

The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.

China: 51.5%Türkiye: 11.5%United States: 10.8%Japan: 7.1%6 others listed: 19.0%52%largest
China4,383 · 51.5%Türkiye982 · 11.5%United States918 · 10.8%Japan602 · 7.1%6 others listed1,618 · 19.0%

Shares of the rows listed above, not of the whole node.

Which institutions lead Inflammatory Biomarkers in Disease Prognosis research?

By volume in 2022-now, Sun Yat-sen University publishes the most Inflammatory Biomarkers in Disease Prognosis research, followed by Capital Medical University and Sichuan University.

By volume, 2022-now

  1. 1 Sun Yat-sen UniversityChina 137 works
  2. 2 Capital Medical UniversityChina 134 works
  3. 3 Sichuan UniversityChina 125 works
  4. 4 Fujian Medical UniversityChina 105 works
  5. 5 Nanjing Medical UniversityChina 103 works
  6. 6 Sağlık Bilimleri ÜniversitesiTürkiye 94 works
  7. 7 Chinese Academy of Medical Sciences & Peking Union Medical CollegeChina 88 works
  8. 8 Chongqing Medical UniversityChina 79 works
  9. 9 Zhejiang UniversityChina 76 works
  10. 10 Wenzhou Medical UniversityChina 74 works

Who are the leading researchers in Inflammatory Biomarkers in Disease Prognosis?

The most-cited researchers publishing on Inflammatory Biomarkers in Disease Prognosis include Douglas G. Altman, Zhong Lin Wang and George Davey Smith.

  1. 1 Douglas G. Altman United Kingdom 862k citations
  2. 2 Zhong Lin Wang United States 491k citations
  3. 3 George Davey Smith United Kingdom 435k citations
  4. 4 Ali H. Mokdad United States 429k citations
  5. 5 Walter Churchill Willett United States 411k citations
  6. 6 John J.V. McMurray United Kingdom 349k citations
  7. 7 Hermann Brenner Germany 343k citations
  8. 8 Emelia J. Benjamin United States 341k citations
  9. 9 Jun Wang China 340k citations
  10. 10 Stephan Windecker Switzerland 338k citations

Ranked by citations received across their whole record, among researchers with at least three works on this topic.

What are the most cited papers in Inflammatory Biomarkers in Disease Prognosis?

The most cited paper in Inflammatory Biomarkers in Disease Prognosis is "Cancer-related inflammation" (Alberto Mantovani, Paola Allavena, Antonio Sica et al., 2008), with 11,477 citations. Next come "Endothelial cell infection and endotheliitis in COVID-19" (6,667) and "C-Reactive Protein and Other Markers of Inflammation in the Prediction of Cardiovascular Disease in Women" (5,889).

Most cited papers
#PaperReleasedCitations
1 Cancer-related inflammation Alberto Mantovani, Paola Allavena, Antonio Sica et al. · Nature Open access Jul 2008 11,477
2 Endothelial cell infection and endotheliitis in COVID-19 Zsuzsanna Varga, Andreas J. Flammer, Peter Steiger et al. · The Lancet Open access 21 Apr 2020 6,667
3 C-Reactive Protein and Other Markers of Inflammation in the Prediction of Cardiovascular Disease in Women Paul M. Ridker, Charles H. Hennekens, Julie E. Buring et al. · New England Journal of Medicine Open access 23 Mar 2000 5,889
4 Inflammation, Aspirin, and the Risk of Cardiovascular Disease in Apparently Healthy Men Paul M. Ridker, Mary Cushman, Meir J. Stampfer et al. · New England Journal of Medicine Open access 3 Apr 1997 5,545
5 Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis Kunihiro Matsushita · The Lancet Open access 18 May 2010 4,213
All 100 most cited papers, with filters and sorting

Where is Inflammatory Biomarkers in Disease Prognosis research done?

The largest centres of Inflammatory Biomarkers in Disease Prognosis research in 2022-now are Beijing (China), Guangzhou (China), Shanghai (China) and Istanbul (Türkiye).

Largest cities, 2022-now

  1. 1 BeijingChina 459 works
  2. 2 GuangzhouChina 267 works
  3. 3 ShanghaiChina 255 works
  4. 4 IstanbulTürkiye 241 works
  5. 5 ChengduChina 203 works
  6. 6 HangzhouChina 157 works
  7. 7 NanjingChina 156 works
  8. 8 AnkaraTürkiye 156 works
  9. 9 ChongqingChina 145 works
  10. 10 FuzhouChina 139 works
See Inflammatory Biomarkers in Disease Prognosis on the map

Where is the best place to study Inflammatory Biomarkers in Disease Prognosis?

Among universities, judged by research, Capital Medical University, Wenzhou Medical University and Sichuan University score highest, combining citation excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.

0%10%20%mean 15.04%fractional works in this field (log) →share of work in the world top 10% →Wenzhou Medical Univ…Capital Medical Univ…Sichuan UniversitySun Yat-sen University
above the meannear itbelow it

One dot per university in the first ten of the table below, at the default weights. The upper left is the interesting corner: small places doing unusually strong work.

Citation excellenceshare of its work in the world top 10%, 2022-now and all time averaged
40%
Specialisationhow much of its work is in this field, counted up to 10× the world share
10%
Sizeits output in this field, on a log scale
30%
Growthoutput growth, counted from -20% to +20%
10%
Internationalshare of its work with a co-author abroad
10%
Each slider sets a weight; the share it gets of the score is beside it.
#UniversityScoreTop 10%SpecialisationWorksGrowth
1Capital Medical UniversityChina 68.413.0%13.5×134 +137.3%
2Wenzhou Medical UniversityChina 66.716.8%15.8×74 +66.9%
3Sichuan UniversityChina 66.312.9%5.9×125 +40.8%
4Sun Yat-sen UniversityChina 65.910.5%7.0×137 +18.9%
5Nanjing Medical UniversityChina 64.813.1%12.4×103 +96.4%
6Chinese Academy of Medical Sciences & Peking Union Medical CollegeChina 63.313.0%8.9×88 +69.3%
7Southern Medical UniversityChina 63.219.0%8.1×47 +54.9%
8Central South UniversityChina 62.918.8%3.4×62 +79.5%
9Harvard UniversityUnited States 62.920.4%1.7×49 -0.2%
10Chongqing Medical UniversityChina 62.512.9%15.0×79 +280.8%

Universities only. The score blends citation excellence (40%), size (30%), specialisation (10%), growth (10%), international reach (10%), 2022-now; growth compares 2018-21 with 2022-25 and counts up to +20%, since a jump from a small base is mostly noise.

Every institution in Inflammatory Biomarkers in Disease Prognosis, country by country

Is Inflammatory Biomarkers in Disease Prognosis research growing?

Output in 2022-2025 was 44% higher than in 2018-2021, peaking in 2025. The fastest-growing topics are Inflammatory Biomarkers in Disease Prognosis.

still counting19801990200020102020
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Its share of all research

Growing output can still be a shrinking share: all of science grows. This is Inflammatory Biomarkers in Disease Prognosis as a percentage of every work published that year, 0.040% in 2024.

still counting0.020%0.040%0.060%Inflammatory Biomarkers in Disease Prognosis0.049% in 202519801990200020102020

Fractional works of Inflammatory Biomarkers in Disease Prognosis over all fractional works that year. How the balance of science has shifted.

How much of it reaches the world top 10%

Year by year.

still counting5%10%15%Inflammatory Biomarkers in Disease Prognosis9.8% in 2025200020102020

Of each year's works in it, the share that reached the world's 10% most cited for their field and year. A field is the world for its own topics, so there is no other line to hold it against.

Which topics inside it are moving

Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.

Discussion

Ask a question or share a note about Inflammatory Biomarkers in Disease Prognosis. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.